Program
Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902
Its studies are mostly in Leukemia, Myeloid, Acute · Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since May 18, 20202 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 21 open or running | phase 1since May 18, 2020 | May 18, 2020 | Jan 19, 2028phase 1 · NCT06788509 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2020First study: phase 1 study in NeoplasmsFirst studyNCT04397276 · 82 enrolled · Canada, Israel, Spain
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509
TargetBeta
“A T-cell redirecting agent and bispecific antibody targeting both the prostate cancer lineage antigen tomoregulin-2 (transmembrane protein with EGF-like and two follistatin-like domains 2; TMEFF2; TENB2) and the T-cell surface receptor CD3, ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Jan 19, 2028 | 120 |
| NCT04397276Neoplasms · Canada, Israel, Spain | 1 | Completed | Sep 16, 2025 | 82 |
How it is read
Names in the registry
- “JNJ-70218902”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.